Biotech Values

[Praveen]

Dew/Coley,

The results are not Ok. They are very good though I don't class them as excellent. Relapsed, treatment-refractory patient population is the key.

PS:I have a position in Coley.

Regards,
Praveen

PS: Also note the mechanism of action. Actilon operates through a dual method of action consisting of both innate and adaptive immunity antiviral mechanisms. Actilon was designed to induce not only the early short-term innate immune effects that temporarily control the virus, but also to trigger adaptive immunity, with a strong killer T cell response, that we believe may provide sustained anti-infective effects. We believe Actilon therapy may allow the duration of HCV therapy to be reduced significantly, thereby resulting in reduced toxicity and improved patient compliance.